NANOVIRICIDES INC (NNVC)

Company Profile

NanoViricides, Inc. is a development stage company, which engages in the development of nanomedicine drugs against viruses. The company is headquartered in Shelton, Connecticut and currently employs 7 full-time employees. The company went IPO on 2004-08-12. The firm's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The company has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. The company is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.

Company Info

NANOVIRICIDES INC

1 Controls Drive

Shelton CONNECTICUT 06484

P: 12039376137

CEO: Anil Diwan

Employees: 7

Website: http://www.nanoviricides.com/